Tag: Acacia Pharma

December 13, 2021 Off

Acacia Pharma completes its post-approval requirement clinical trial testing Barhemsys in individuals with severe renal impairment

Acacia Pharma Group has completed its post-approval requirement clinical trial investigating the effects of BARHEMSYS® (amisulpride injection) in individuals with severe renal impairment.

February 13, 2017 Off

Acacia Pharma’s PONV drug Baremsis meets goals, next step submitting to the FDA

By Dino Mustafić

Acacia Pharma Group has made final pivotal Phase 3 study testing amisulpride injection Baremsis, formerly APD421, for patients with post-operative nausea & vomiting (PONV), after getting antiemetic prophylaxis, and now all phases met primary endpoints.